356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumors
Scott Boiko(Ensemble Therapeutics (United States)), Robert Svensson(Malmö University), Frederik Bartels, J M Alexander(Cardiovascular Institute Hospital), Angela V. Toms, Anita Scheuber(Nimbus (Italy)), Justin A. Caravella(Rockefeller University Press), Peter J. Tummino(Intarcia Therapeutics (United States)), Samantha Carreiro(Ensemble Therapeutics (United States)), Silvana Leit, Di Li(Physical Research Laboratory), Zhigui Li, Hyongmin Oh, Yuet Mei Khong(Ensemble Therapeutics (United States)), Avinash Phadke(Achillion Pharmaceuticals (United States)), Beth Browning(Ensemble Therapeutics (United States)), E. Florine, Suzanne Jacques-O’Hagan(Ensemble Therapeutics (United States)), S. Britt, Nikolay S. Sitnikov
Cited by 0
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550